ActRx Operational Group, Ltd. is an international pharmaceutical company, engaged with a team of highly skilled medical practitioners performing groundbreaking research, development, clinical trials, GMP manufacturing and global distribution of primarily herbal-based medicines for the safe and effective treatment of globally critical diseases, such as Dengue, Malaria, as well as other infectious and tropical diseases.
Ongoing Research and Development, as well as Clinical Trials for other diseases, such as Zika, Chikungunya, West Nile Virus, Japanese Encephalitis, Yellow Fever, Sleeping Sickness and a host of others are already under review and, in some cases, work is already in progress toward a treatment and/or cure.
Clinical Trials have recently established the Safety and Efficacy of the ActRx TriAct® combination for the treatment of Dengue.
ActRx TriAct® is the newest, patent-pending Dengue treatment, developed as a totally oral treatment and produced exclusively by ActRx Operational Group, Ltd.
Dengue (or Dengue Fever as it sometimes called) and Malaria, were initially chosen for intensive research, study and clinical trials due to epidemic-level prevalence worldwide. Dengue alone now presents over 392 million cases per year, affecting over 140 nations. There is presently no successful, proven treatment worldwide to stop its overwhelming mortality, especially in children. Modern medicine currently offers no effective treatment for Dengue, other than the very limited symptomatic relief, as outlined by the World Health Organization (WHO) in a Standard of Care for Dengue.
Malaria prevalence follows Dengue, with an estimate of over 207 million cases per year worldwide. Only limited levels of successful medical treatment exist, considering various factors such as resistance levels, drug effectiveness and availability.
Proposed ActRx Factory & Laboratory Facilities
designed by SCDI
Shown right: Normal View (Front)